葵花药业及相关人员收到黑龙江证监局警示函

Core Points - The company received a warning letter from the Heilongjiang Securities Regulatory Bureau regarding violations of disclosure regulations related to a related party transaction [1][2] - The transaction involved a procurement deal with Shanghai Haiwei Biotechnology Co., a wholly-owned subsidiary of a related entity, totaling 32.38 million yuan, which is 0.68% of the company's latest audited net assets [1] - The company's chairman, general manager, and board secretary were found primarily responsible for failing to fulfill their diligence obligations [1] Summary by Sections - Regulatory Action - The Heilongjiang Securities Regulatory Bureau issued a warning letter to the company and its executives as an administrative regulatory measure [2] - The warning will be recorded in the securities and futures market integrity archives [2] - Transaction Details - The related party transaction involved a total amount of 32.38 million yuan [1] - This amount represents 0.68% of the company's most recent audited net assets [1] - Responsibility - The chairman, general manager, and board secretary of the company did not comply with the required diligence obligations, leading to their accountability for the violations [1]